anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Magnesium Sulfate
Trial phase: Phase 1 | Phase 2
ATC code: A06AD04 | A12CC02 | B05XA05 | D11AX05 | V04CC02
SMILES: O=S(=O)([O-])[O-].[Mg+2]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Regional only 0.75 mg Magnesium Sulfate (50% Total Dose): 5 patients

Magnesium Sulfate: Intra-arterial
Eligibility criteria:
Inclusion Criteria:

Patient with acute cerebral ischemia due to ICA or MCA occlusion,
Patient's clinical attending physician plans mechanical embolectomy procedure as part of routine clinical care.
Age 21-95.

Exclusion Criteria:

Severe renal impairment with creatinine 3.0 or higher,
Myasthenia gravis,
Second or third degree heart block without a pacemaker in place,
Technical inability to navigate microcatheter to target clot,
Patient already enrolled in another experimental treatment trial. Exclusion criteria 1-3 are all contraindications to magnesium therapy.
Intervention: Creatine monohydrate
Trial phase: Not Applicable
SMILES: CN(CC(=O)O)C(=N)N.O
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 40
Group description: Citicoline, Omega-3 Fatty Acids and Creatine: Citicoline: 500 mg/day for 28 days Omega-3 Fatty Acids: 2 g/day for 28 days Creatine: 5 g/day for 28 days
Eligibility criteria:
Inclusion Criteria:

Female
Age 40-60 years

Exclusion Criteria:

Significant medical condition
History of co-morbid psychiatric disorders
Current Axis I or II diagnosis
Past participation in a pharmacotherapeutic trial
Head injury with LOC>5 minutes
Use of psychotropic medication
History of fish allergies
Medical condition associated with clinically significant decreases in coagulability
Use of anticoagulant medication
Intervention: Resveratrol
Trial phase: Phase 2
SMILES: Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 64
Group description: 60 subjects will take 500 mg by mouth once daily increasing at 13 week intervals to a maximum of 1 gram by mouth twice daily with or without food.

Resveratrol: The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).
Eligibility criteria:
Inclusion Criteria:

Diagnosis of probable AD (NINDS-ADRDA criteria).
Age must be 50 years or older.
Able to ingest oral medications.
Caregiver/Study Partner who has direct contact with the participant more than 2 days per week to accompany participant to all visits.
MMSE score between 14 and 26 (inclusive).
Modified Hachinski score of less than or equal to 4.
Able to abstain from ingesting large quantities of resveratrol-containing foods (including red wine). 1-2 glasses of red wine or red grape juice daily acceptable; 1 serving of red grapes daily acceptable.
Able to abstain from ingesting herbal/natural preparations or dietary supplements containing resveratrol.

Exclusion Criteria:

Non-AD dementia.
Probable AD with Down syndrome.
History of clinically significant stroke.
Current evidence or history in past two years of epilepsy, focal brain lesion, head injury with loss of consciousness or DSM-IV criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse.
Sensory impairment that would preclude the participant from participating in or cooperating with the protocol.
Use of investigational agent within two months of Screening.
Evidence of any significant clinical disorder or laboratory finding that renders the participant unsuitable for receiving an investigational drug including clinically significant or unstable hematologic, hepatic, cardiovascular, pulmonary, gastrointestinal, endocrine, metabolic, renal or other systemic disease or laboratory abnormality.
Active neoplastic disease, history of cancer five years prior to screening, including breast cancer (history or skin melanoma or stable prostate cancer are not excluded).
History of seizure within past five years.
Pregnancy or possible pregnancy.
Use of resveratrol containing supplements.
Intervention: ASPIRIN
Trial phase: Phase 2
ATC code: A01AD05 | B01AC06 | B01AC56 | C07FX02 | C07FX03 | C07FX04 | C10BX01 | C10BX02 | C10BX04 | C10BX05 | C10BX06 | C10BX08 | C10BX12 | M01BA03 | N02AJ02 | N02AJ07 | N02AJ18 | N02BA01 | N02BA51 | N02BA71
SMILES: CC(=O)Oc1ccccc1C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 195
Group description: This arm received a 325mg loading dose of aspirin on study day one, followed by 81mg of aspirin on days 2-7.
Eligibility criteria:
Inclusion Criteria:

Adult patients (age > 18) admitted to the hospital through the emergency department (ED)
At high risk of developing acute lung injury (ALI) Lung Injury Prediction Score (LIPS) greater than or equal to 4

Exclusion Criteria:

Anti-platelet therapy on admission or within 7 days prior to admission
Presented to outside hospital ED > 12 hrs before arrival at site's facility
Inability to obtain consent within 12 hours of hospital presentation
Admitted for elective surgery
Acute lung injury prior to randomization
Receiving mechanical ventilation through a tracheostomy tube prior to current hospital admission (patient who is ventilator dependent)
Presence of bilateral pulmonary infiltrates on admission if he or she has a history of bilateral pulmonary infiltrates (as evidenced by previous x-rays) that can reasonably explain the current degree of pulmonary infiltrates present.
Presentation due to pure heart failure and no other known risk factors for ALI.
Allergy to aspirin or non steroidal anti inflammatory drugs (NSAIDs)
Bleeding disorder
Suspected active bleeding or judged to be at high risk for bleeding
Active peptic ulcer disease (within past 6 months)
Severe chronic liver disease
Inability to administer the study drug
Expected hospital stay < 48 hours
Admitted for comfort or hospice care
Patient, surrogate or physician not committed to full support. (Exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest)
Not anticipated to survive > 48 hours
Previously enrolled in this trial
Enrolled in a concomitant intervention trial
Pregnant or breastfeeding
Intervention: Melatonin
Trial phase: Not Applicable
ATC code: N05CH01
SMILES: COc1ccc2[nH]cc(CCNC(C)=O)c2c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 50
Group description: Melatonin: 5mg of melatonin will be taken by the subject for 3 nights prior and continuing 3 nights after surgery as tolerated.
Eligibility criteria:
Inclusion Criteria:

Patients 18-90 years old undergoing elective, primary total knee replacement
American Society of Anesthesiologists (ASA) Physical Status I-III
Epidural anesthesia/Patient Controlled Analgesia candidate

Exclusion Criteria:

Mental impairment
Pre-operative use of benzodiazepines, narcotics, or prescription/over-the counter (OTC) sleep aids
Pre-operative use of calcium channel blockers
Insomnia
Recent drug or alcohol abuse
Psychiatric disorders other than anxiety, including depression
Diabetes
Intervention: Victoza
Trial phase: Phase 4
ATC code: A10BJ02
SMILES: CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1ccccc1)C(=O)NC(C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C)C(C)CC)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 35
Group description: Liraglutide: Liraglutide 1.8mg injected subcutaneously from pen device once daily for 6-months
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetes mellitus
Insulin dose of >1.8 units/kg/day (represents total daily insulin dose, regardless of formulation, regimen, number of daily shots)
HbA1c ≥ 7.5% and ≤ 11%
Age ≥ 18
Stable comorbidities on stable treatment regimens
Stable dose of all oral hypoglycemics for ≥ 3 months prior to enrollment
Ability to provide informed consent before any trial-related activities

Exclusion Criteria:

Type 1 diabetes mellitus
Any contraindication to the MRI procedure (metallic implants, severe claustrophobia, pregnancy, unable to lie still on a hard table for the duration of the procedure, weight above 400 lb - limit of the MRI table, magnet's inner circumference smaller than the largest body circumference)
History of any pancreatic disease as it might interfere with the pancreatic TG measurement (i.e. pancreatitis, tumors, cysts, type 1 diabetes, any pancreatic surgery)
End Stage Renal Disease on dialysis due to increased risk of hypoglycemia, and possible interference with accurate measurement of HbA1c
Incretin therapy (any GLP-1 agonist or DPP-IV inhibitor)
Unstable or decompensated comorbidities
Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome
Severe gastroparesis
Pregnancy, breast feeding, intention to become pregnant, or not using adequate contraceptive measures
Organ transplant recipient or waiting list candidate
Steroid use (current or potential use during the trial)
Known/suspected allergy to trial medication, excipients, or related products
Contraindications to study medications, worded specifically as stated in the product's prescribing information
Non-English speaking volunteers since no interpreters are available and the safety of the volunteers could be jeopardized if adequate and reliable communication is not possible.
Intervention: SODIUM CHLORIDE
Trial phase: Phase 4
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 36
Group description: Saline: Placebo injection of 1.8mg saline once daily for 6-months
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetes mellitus
Insulin dose of >1.8 units/kg/day (represents total daily insulin dose, regardless of formulation, regimen, number of daily shots)
HbA1c ≥ 7.5% and ≤ 11%
Age ≥ 18
Stable comorbidities on stable treatment regimens
Stable dose of all oral hypoglycemics for ≥ 3 months prior to enrollment
Ability to provide informed consent before any trial-related activities

Exclusion Criteria:

Type 1 diabetes mellitus
Any contraindication to the MRI procedure (metallic implants, severe claustrophobia, pregnancy, unable to lie still on a hard table for the duration of the procedure, weight above 400 lb - limit of the MRI table, magnet's inner circumference smaller than the largest body circumference)
History of any pancreatic disease as it might interfere with the pancreatic TG measurement (i.e. pancreatitis, tumors, cysts, type 1 diabetes, any pancreatic surgery)
End Stage Renal Disease on dialysis due to increased risk of hypoglycemia, and possible interference with accurate measurement of HbA1c
Incretin therapy (any GLP-1 agonist or DPP-IV inhibitor)
Unstable or decompensated comorbidities
Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome
Severe gastroparesis
Pregnancy, breast feeding, intention to become pregnant, or not using adequate contraceptive measures
Organ transplant recipient or waiting list candidate
Steroid use (current or potential use during the trial)
Known/suspected allergy to trial medication, excipients, or related products
Contraindications to study medications, worded specifically as stated in the product's prescribing information
Non-English speaking volunteers since no interpreters are available and the safety of the volunteers could be jeopardized if adequate and reliable communication is not possible.
Intervention: Propofol
Trial phase: Phase 2
ATC code: N01AX10
SMILES: CC(C)c1cccc(C(C)C)c1O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 24
Group description: Propofol: After inhalation induction with 6% in sevoflurane in O2:N2O (30:70),administer propofol bolus at 3mg/kg,followed by an infusion of propofol at 240mcg/kg/min. Upper airway images will be obtained when expired sevoflurane is 0
Eligibility criteria:
Inclusion Criteria:

Children undergoing MRI brain
Age 2 - 5 yrs
ASA I - II

Exclusion Criteria:

OSA
Pathology of upper airway
Craniofacial anomalies
Gastroesophageal reflux
Increased intracranial pressure
Body weight of 20% more than ideal
Contraindication to the use of either drug
Failure to maintain a patent airway during the study
Intervention: Gabapentin
Trial phase: Phase 2
ATC code: N02BF01 | N03AX12
SMILES: NCC1(CC(=O)O)CCCCC1
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 25
Group description: Active treatment arm.

gabapentin: Participants randomized to the active treatment arm will receive gabapentin 20mg/kg/day PO divided into 3 doses and rounded to the nearest 100 mg for capsules and 10 mg for liquid preparation.
Eligibility criteria:
Inclusion Criteria:

Participant is enrolled on Total XVI or who are being treated "as per TOTXVI protocol"
Participant is 1 year of age or older
Participant has symptoms of NP/PN with onset no more than 7 days after one of the following vincristine doses ± 3 days: protocol week 1, week 2 (induction), week 7 (reinduction I), or week 17 (reinduction II).
Patient is expected to receive 2 doses of vincristine in weekly intervals as outlined by the Total XVI protocol (or for those being treated "as per TOTXVI" protocol) while on study drug (i.e. no known dosage reductions or planned missed doses).

Participant is able and willing to take oral medications.

Exclusion Criteria:

Previous participation in this study
Participant is receiving gabapentin for another indication at the time of diagnosis of NP/PN or has received gabapentin previously.
Pregnancy. Female participants of childbearing potential must have documented negative urine or serum pregnancy test result not older than 7 days. Male patients with reproductive potential will be counseled not to procreate during the study.
Impaired renal function: decreased eGFR (<60ml/min/1.73m^2 as estimated by the revised Schwartz equation)
Participant has allergy or other contraindication for either morphine or gabapentin therapy.
Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
Intervention: Axitinib
Trial phase: Phase 2
ATC code: L01EK01 | L01XE17
SMILES: CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Axitinib 5mg twice daily for 28 days followed by concurrent axitinib plus hypofractionated radiation therapy (45 Gy in 15 fractions) followed by maintenance axitinib 5mg twice daily until progression or unacceptable toxicity

Axitinib: 5 mg twice daily starting 21 days after resection and continuing until progression or unacceptable toxicity

Radiation Therapy: 45 Gy in 15 fractions starting after 28 days of Axitinib monotherapy
Eligibility criteria:
Inclusion Criteria:

Newly diagnosed patients with histologically proven glioblastoma multiforme
Age above 70 years
Karnofsky score of 50-80
Adequate organ function as defined by laboratory values
Life expectancy of >12 weeks
No evidence of preexisting uncontrolled hypertension as documented by 2 baseline blood pressure readings taken at least 1 hour apart. The baseline systolic blood pressure readings must be 140 mm Hg, and the baseline diastolic blood pressure readings must be 90 mm Hg. Patients whose hypertension is controlled by antihypertensive therapies are eligible.

Exclusion Criteria:

Prior treatment with chemotherapy or radiation for glioblastoma multiforme
Patients with extensive tumor hemorrhage
Any of the following within the 12 months prior to study drug administration: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack and 6 months for deep vein thrombosis or pulmonary embolism
Intervention: Pentoxifylline
Trial phase: Phase 2
ATC code: C04AD03 | R03DA20
SMILES: CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 31
Group description: Trental 400 mg TID and Vitamin E 400IU BID starting the first day after the last radiosurgery treatment

Trental: 400 mg tid starting first day after last radiosurgery treatment and continuing for 6 months

Vitamin E: 400IU twice daily starting the first day after last radiosurgery treatment and continuing for 6 months
Eligibility criteria:
Inclusion Criteria:

Plan to undergo single or five fraction radiosurgery for a metastatic brain tumor
Diagnosis of a metastatic brain tumor may be accomplished by histologic confirmation or by clinical confirmation by the treating physician based on MR imaging characteristics in the setting of a known history of cancer
Age > 18 years
Partial or total resection of a metastatic tumor are eligible

Exclusion Criteria:

Known sensitivity to vitamin E or Trental
Recent intracranial bleed or retinal hemorrhage
Treatment with a non-approved or investigational drug within 30 days before day 1 of study treatment
History of Avastin treatment
Anticipated need for treatment with Avastin
History of bleeding disorder
History of liver disorder
Intervention: Metoprolol
Trial phase: Phase 4
ATC code: C07AB02 | C07BB02 | C07BB52 | C07CB02 | C07FB02 | C07FB13 | C07FX03 | C07FX05
SMILES: COCCc1ccc(OCC(O)CNC(C)C)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 93
Group description: Subjects received metoprolol succinate (Betaloc SR) at a dose of 47.5 mg once daily orally as SR tablets for a period of 4 weeks. The dose of metoprolol was escalated to 71.25 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 95 mg orally once daily for the next 4 weeks (Weeks 8 to 12) if clinic SBP was >=140 mmHg and/or DBP was >=90 mmHg measured every 4 weeks.
Eligibility criteria:
Inclusion Criteria:

Subjects aged: >=18 years and =<70 years old
EH who are suitable for mono-therapy, either mild to moderate EH patients who have not been treated with anti-hypertension drugs, or mild EH subjects who have taken anti-hypertension drug.
Clinic resting Heart Rate >=70 beats per minute (bpm)
Patients who have signed informed consent

Exclusion Criteria:

Subjects with contraindications according to the China Summary of Product Characteristics (SmPCs) of both bisoprolol and metoprolol SR, such as acute heart failure, second or third degree atrioventricular block (without a pacemaker), sick sinus syndrome, symptomatic bradycardia or symptomatic hypotension, severe bronchial asthma or severe chronic obstructive pulmonary disease, metabolic acidosis, etc.
Moderate EH patients who have used anti-hypertension drugs
Secondary hypertension
Subjects with history of coronary heart disease
Chronic or acute heart failure
Cerebrovascular events within 6 months before screening
Impaired hepatic or renal function (according to local lab standard)
Other protocol defined exclusion criteria could apply
Intervention: Cholecalciferol
Trial phase: Phase 2
ATC code: A11CC05 | A11CC55 | M05BB03 | M05BB04 | M05BB05 | M05BB07 | M05BB08 | M05BB09 | M05BX53
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)CCCC(C)C)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)CCC1=C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 56
Group description: Vitamin D3: cholecalciferol capsule, 600 IU, daily for 6 months
Eligibility criteria:
Inclusion Criteria:

Age ≥ 18 years
Women with a history of stage I-IIIa invasive breast cancer
History of hormone-receptor positive cancer (either ER + or PR + or both)
Are prescribed and are taking anastrozole, letrozole or exemestane for at least one month and have at least 7 months of AI treatment remaining
Are experiencing AIMSS

Exclusion Criteria:

Unable to read or understand English
History of psychiatric disability affecting informed consent or compliance with drug intake
Malabsorption syndrome or inability to take oral medication
Has less than 7 months of AI therapy remaining
Intervention: Varenicline
Trial phase: Phase 3
ATC code: N07BA03 | S01XA28
SMILES: c1cnc2cc3c(cc2n1)C1CNCC3C1
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 77
Group description: Participants >55 kg will take varenicline 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily for 11 weeks. Participants ≤55 kg will take varenicline 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily for 11 weeks.

Varenicline: participants >55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
Eligibility criteria:
Inclusion Criteria:

Age 14-21
Daily smoker for ≥6 months
Desire to quit smoking, with at least one prior failed quit attempt and willingness to participate in a treatment study
If under age 18, parent(s) or guardian(s) able to participate in informed consent and initial assessment (unless the participant provides evidence of emancipated status)
If female, agreement to use birth control (any form of hormonal contraception such as Depo-Provera, daily oral contraception, transdermal patch, or Nuva-ring; intrauterine device; sterilization; or double barrier contraception, which is a combination of any two of the following methods: condoms, spermicide, diaphragm) to avoid pregnancy

Exclusion Criteria:

Lifetime history of any DSM-IV-TR mood or psychotic disorder (e.g., major depressive disorder, bipolar disorder, schizophrenia)
Lifetime history of suicidality, homicidality, or clinically significant hostility/aggression
Current substance dependence, other than nicotine
Current unstable major medical disorder
Current pregnancy or breastfeeding
Current use of medications with smoking cessation efficacy
Known hypersensitivity to varenicline